T-W. Park-Simon

Trastuzumab s . c . beim HER 2-positiven Mamma-karzinom – Evidenz und Erfahrungen aus der praktischen Anwendung in 7 deutschen Zentren Subcutaneous Trastuzumab for HER 2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers

H. Tesch, C. Jackisch, V. Müller, 2015 .

Subcutaneous Trastuzumab for HER2-positive Breast Cancer – Evidence and Practical Experience in 7 German Centers

H. Tesch, C. Jackisch, V. Müller, 2015, Geburtshilfe und Frauenheilkunde.

Abstract P4-08-26: Validation of different prognostic scores in breast cancer patients with brain metastases of the BMBC registry (GBG-79)

P. Fasching, T. Fehm, S. Loibl, 2019, Poster Session Abstracts.

Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry

T. Fehm, C. Denkert, V. Nekljudova, 2022, ESMO open.

Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry

T. Fehm, C. Denkert, V. Nekljudova, 2022, ESMO open.

P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer

L. Paz-Ares, W. Edenfield, F. Braiteh, 2019, International Journal of Gynecological Cancer.